联环药业：盐酸林可霉素注射液通过仿制药一致性评价

Group 1 - The core point of the article is that Lianhuan Pharmaceutical's subsidiary, Xinxiang Changle Pharmaceutical Co., Ltd., has successfully passed the consistency evaluation for the quality and efficacy of Lincomycin Hydrochloride Injection [1] - In 2025, Changle Pharmaceutical obtained a total of 2 production licenses [1] - The research and development investment for the consistency evaluation has reached approximately 2.328 million yuan [1] Group 2 - In 2024, the domestic sales revenue of Lincomycin Hydrochloride Injection in sample hospitals amounted to 10.8176 million yuan [1]